Tempest Therapeutics Inc. (TPST), a clinical-stage biotechnology company, on Friday reported a definitive agreement of the immediate exercise of outstanding warrants and announced the issue of new short-term warrants.
Following the announcement, shares dropped over 10% on Friday.
The company will exercise outstanding warrants to purchase 1,172,414 shares of the company's common stock at a reduced exercise price of $1.73 per share, issued originally in November 2025 at an exercise price of $3.50 per share.
The closing of the warrant exercise transaction is expected to be May 29, 2026.The company will issue new unregistered short-term warrants to purchase up to 2,344,828 shares of common stock at $1.73 per share.
It is estimated that the gross proceeds from the warrant exercise will amount to $2 million, and additional potential gross proceeds of $4 million may be gained from the new short-term warrants.
TPST is currently trading at $1.54, down 10.54%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.